{"entity":{"id":"nct00383708","kind":"trial","name":"Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients","aka":[],"tldr":"A phase 3 trial of Somatostatin analogues and Pegvisomant in Pituitary tumours, run by Ipsen, completed.","summary":"Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients is a phase 3 interventional study registered as NCT00383708 by Ipsen, with 125 participants recorded, started 2006-10 and reaching its primary completion in 2008-10. Interventions recorded: lanreotide (Autogel formulation), Pegvisomant. Conditions recorded: Acromegaly.\n\nLinked to the drug Pegvisomant because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00383708","url":"https://clinicaltrials.gov/study/NCT00383708"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pituitary-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["octreotide-lanreotide","pegvisomant"],"companies":["ipsen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00383708","phase":"3","setting":"Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg Alone","sponsor":"Ipsen","started":"2006-10","yearReported":2018,"enrolled":125,"enrolledBasis":"registry","outcomes":[{"endpoint":"Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period","primary":true,"unit":"%","arms":[{"name":"Lanreotide Autogel + Pegvisomant Co-administration","n":57,"value":57.9,"note":"Figures from the ClinicalTrials.gov results section (first posted 2018-07-23), not from a publication"}],"p":"<0.0001","source":"https://clinicaltrials.gov/study/NCT00383708?tab=results"}]},"route":"/trials/nct00383708/","neighbours":{"cancer":[{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/"}],"drug":[{"id":"pegvisomant","kind":"drug","name":"Pegvisomant","route":"/drugs/pegvisomant/"},{"id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/"}],"company":[{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/"}]}}